Abstracts Archive - Page 2475 of 2605 - ACR Meeting Abstracts

Abstract Number: 1906 • 2012 ACR/ARHP Annual Meeting
Changes in Gout patient´s Clinical Profile in the Last Two Decades
Fernando Perez-Ruiz¹ and Ana M. Herrero-Beites², ¹Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain, ²Physical Medicine Division, Hospital de Gorliz, Gorliz, Spain
Background/Purpose: to assess whether changes in the clinical profile of gout are observed in a large cohort of gout patients over the last 20 years.…
Abstract Number: 1907 • 2012 ACR/ARHP Annual Meeting
Pharmacological Management of Gout in Italy in the Years 2005-2009: A Nationwide, Population-Based Study
Lorenzo Cavagna¹, Gianluca Trifirò², Roberto Caporali³, P. Morabito², C. Ferrajolo⁴, S. Pecchioli⁵, M. Simonetti⁵, G. Medea⁶, C. Cricelli⁷, A. Caputi², G. Mazzaglia⁵ and Carlomaurizio Montecucco⁸, ¹Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ²Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Italy, ³Division of Rheumatology, IRCCSPoliclinico S. Matteo Foundation, Pavia, Italy, ⁴Department of Experimental Medicine, Pharmacology Section, Second University of Naples, Naples, Italy, ⁵Health Search, Italian College of General Practitioners, Italy, ⁶Italian college of General Practitioner, Italy, ⁷Italian college of General Practitioner, Pavia (italy), Italy, ⁸Division of Rheumatology, University of Pavia School of Medicine, IRCCS Policlinico San Matteo Foundation, Pavia, Italy
Background/Purpose: Despite the increasing interest on gout, only few nationwide drug utilization studies have been conducted on this topic. The aim of this study…
Abstract Number: 1908 • 2012 ACR/ARHP Annual Meeting
Multinational Evidence-Based Recommendations for Diagnosis and Management of Gout: Integrating Systematic Literature Research and Expert Opinion of a Broad Panel of Rheumatologists in the 3E Initiative
Mariano Andres¹, Francisca Sivera², Alison Kydd³, John Moi⁴, Rakhi Seth⁵, Melonie K. Sriranganathan⁶, Caroline van Durme⁷, Irene AAM van Echteld⁸, Ophir Vinik⁹, Mihir D. Wechalekar¹⁰, Daniel Aletaha¹¹, Claire Bombardier⁹, Rachelle Buchbinder¹², Loreto Carmona¹³, Christopher J. Edwards¹⁴, R. Landewe¹⁵ and Désirée van der Heijde¹⁶, ¹Seccion Reumatologia, Hospital General Universitario de Alicante, Alicante, Spain, ²Sección de Reumatología, Hospital General Universitario de Elda, Alicante, Spain, ³Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁴Royal Melbourne Hospital, Melbourne, Australia, ⁵Rheumatology, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ⁶Rheumatology, St. Mary's Hospital, Isle of Wight, United Kingdom, ⁷Maastricht University Medical Centre, Maastricht, Netherlands, ⁸Atrium Medical Center, Heerlen, Netherlands, ⁹Rheumatology, University of Toronto, Toronto, ON, Canada, ¹⁰Flinders University School of Medicine, Adelaide, Australia, ¹¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ¹²Monash Department of Clinical Epidemiology at Cabrini Hospital, Department of Epidemiology and Preventive Medicine, Monash University, Malvern, Victoria, Australia, ¹³Health Sciences School, Universidad Camilo José Cela, Villanueva de la Cañada, Spain, ¹⁴NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ¹⁵Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ¹⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The 3e (Evidence, Expertise, Exchange) Initiative is a multinational collaboration that aims to promote evidence-based medicine in rheumatology. The 2011-12 3e Initiative aimed to…
Abstract Number: 1909 • 2012 ACR/ARHP Annual Meeting
Use of Uric Lowering Therapies within a Large Health Care System
Robert A. Overman¹, Brian F. Mandell² and Chad L. Deal³, ¹Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ²Dept of Rheum/Immun NA10, The Cleveland Clinic, Cleveland, OH, ³Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH
Background/Purpose: Guidelines for initiating urate lowering therapy (ULT) in the treatment of gout recommend treatment to a target serum urate (SUA) level of ≤6mg/dl with…
Abstract Number: 1910 • 2012 ACR/ARHP Annual Meeting
Regulation of Microrna 223 Expression in a Gouty Arthritis
Gianina Statache¹, Ashleigh-Ann Rainey¹, Seth Masters², Andra Balanescu³, Iain B. McInnes⁴ and Mariola Kurowska-Stolarska⁵, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Immunology Research Centre, Trinity College Dublin, Dublin, United Kingdom, ³Internal Medicine and Rheumatology, University of Medicine and Pharmacy, Bucharest, Romania, ⁴University of Glasgow, Glasgow, United Kingdom, ⁵Institute of Infection,Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Gout is an inflammatory chronic disease caused by deposition of uric acid crystals in the joint and connective tissues causing pain and disability. Current…
Abstract Number: 1911 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab Vs Triamcinolone Acetonide in Patients with Gouty Arthritis Unable to Use Nonsteroidal Anti-Inflammatory Drugs and Colchicine, and On Stable Urate Lowering Therapy (ULT) or Unable to Use ULT
T. Bardin¹, A. So², R. Alten³, M. Bloch⁴, M. R. John⁵, G. Krammer⁵, J. M. Nebesky⁵, A. Tao⁶ and N. Schlesinger⁷, ¹Service de Rhumatologie, Hôpital Lariboisière, Paris, France, ²Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland, ³Charité Univ Medicine, Berlin, Germany, ⁴Holdsworth House Medical Practice, Sydney, Australia, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: The primary treatment goals for gouty arthritis (GA) are rapid relief of pain and inflammation during acute attacks, and long-term hyperuricemia management. A post-hoc…
Abstract Number: 1912 • 2012 ACR/ARHP Annual Meeting
Colchicine, As Assessed by Target Joint Pain Scores, Is Effective At 16 Hours in Patients with Acute Gout Flares
Suman Wason¹, Thomas Lauterio¹, Steve Crockett¹ and Matthew W. Davis², ¹Clinical Development, URL Pharma, Philadelphia, PA, ²Clinical Pharmacology, URL Pharma, Philadelphia, PA
Background/Purpose: The management of patients with gout remains suboptimal, leading to increasing frequency and severity of recurrent flares that eventually lead to joint destruction and…
Abstract Number: 1913 • 2012 ACR/ARHP Annual Meeting
Complete Tophus Response in Patients with Chronic Gout Initiating Pegloticase Treatment
Michael A. Becker¹, Neil J. Gonter², Janet E. Pope³, Raymond L. Malamet⁴ and Herbert S. B. Baraf⁵, ¹Medicine, University of Chicago, Chicago, IL, ²Rheumatology Associates of North Jersey, Teaneck, NJ, ³Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ⁴Global Medical Affairs, Savient Pharmaceuticals, Inc., Bridgewater, NJ, ⁵Arthritis & Rheumatism Associates, Wheaton, MD
Background/Purpose: Pegloticase, a recombinant modified mammalian uricase that acts via enzymatic degradation of uric acid to allantoin, is approved in the US for the treatment…
Abstract Number: 1914 • 2012 ACR/ARHP Annual Meeting
The Diagnosis and Management of Gout in 2012: Survey of US and Canadian Rheumatologists
John J. Cush¹ and Robert T. Keenan², ¹Baylor Research Institute, Dallas, TX, ²Rheumatology, Duke University, Durham, NC
Background/Purpose: The introduction of novel treatment modalities for gout has escalated interest and education on this topic. Although gout is the most common inflammatory arthropathy…
Abstract Number: 1915 • 2012 ACR/ARHP Annual Meeting
Elevated Serum Homocysteine Levels Were Related Not with Serum Uric Acid Levels but with Decreased Renal Function in Chronic Gouty Patients
Sang Tae Choi¹, Jung-Soo Song¹, Jin Su Kim², Eun-Jin Kang³, Kwang-Hoon Lee⁴ and You-Jung Ha⁵, ¹Rheumatology, Chung-Ang University College of Medicine, Seoul, South Korea, ²Chung-Ang University College of Medicine, Seoul, South Korea, ³Rheumatology, Busan Medical Center, Busan, South Korea, ⁴Dongguk University Ilsan Hospital, Goyang, South Korea, ⁵Kwandong University college of Medicine, Goyang, South Korea
Background/Purpose: Hyperhomocysteinemia, which is related with cardiovascular diseases and metabolic syndrome, is regarded as one of the important factors in endothelial cell damage processes. It…
Abstract Number: 1916 • 2012 ACR/ARHP Annual Meeting
Serum Uric Acid As a Biomarker for Mitigation of Infusion Reactions in Patients Treated with Pegloticase for Refractory Chronic Gout
Herbert S. B. Baraf¹, Robert A. Yood², John S. Sundy³, Faith D. Ottery⁴ and Michael A. Becker⁵, ¹Arthritis & Rheumatism Associates, Wheaton, MD, ²Reliant Medical Group, Worcester, MA, ³Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, ⁴Medical Affairs, Savient Pharmaceuticals, Inc., East Brunswick, NJ, ⁵Medicine, University of Chicago, Chicago, IL
Background/Purpose: Using data pooled from the randomized, placebo-controlled trials (RCTs) of pegloticase, post-hoc analyses of urate-lowering, antibody titers and the patterns of infusion-related reactions (IRs)…
Abstract Number: 1917 • 2012 ACR/ARHP Annual Meeting
Long-Term Follow-up of IgG4-Related Diseases Presenting with Lacrimal and Salivary Gland Involvement
Hiroki Takahashi¹, Motohisa Yamamoto¹, Tetsuya Tabeya¹, Chisako Suzuki¹, Yasuyoshi Naishiro¹, Yasuhisa Shinomura¹ and Kohzoh Imai², ¹First Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan, ²The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
Background/Purpose: IgG4-related disease (IgG4-RD) is a recently recognized disease entity that is characterized by tumefactive and hyperplastic lesions in various organs including the lacrimal and…
Abstract Number: 1918 • 2012 ACR/ARHP Annual Meeting
Cluster Analysis of Organ Involvements Patients with Serum IgG4 Elevation; IgG4–related Disease Is a Distinct Subtype of Patients with Hyper-IgG4
Masamitsu Tatewaki, Kazuhiro Kurasawa, Ayae Tanaka, Junya Nagasawa, Satoko Arai, Reika Maezawa, Takayoshi Owada and Takeshi Fukuda, Clinical Immunology, Dokkyo Medical University, Mibu, Tochigi, Japan
Background/Purpose: IgG4-related disease (IgG4-RD) is a multi-organ affecting disease characterized by fibroinflammatory lesions with a abundant IgG4-positive plasma cells infiltration. This disorder includes many…
Abstract Number: 1879 • 2012 ACR/ARHP Annual Meeting
Work Related Injuries Causing or Aggravating Fibromyalgia in the Medicolegal Arena: A Jurisprudential Analysis
Mary-Ann Fitzcharles¹, Peter A. Ste-Marie² and Yoram Shir³, ¹Rheumatology and Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ²University of Montreal, Montreal, QC, Canada, ³Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Up to 40% of persons report onset of fibromyalgia (FM) following a “triggering event”. Injuries, which may occur in the workplace, may be implicated…
Abstract Number: 1880 • 2012 ACR/ARHP Annual Meeting
A Brazilian Portuguese Validation of the Revised Fibromyalgia Impact Questionnaire (FIQR)
Eduardo S. Paiva¹, Roberto E. Heymann², Marcelo C. Rezende³, Milton Helfenstein Jr.⁴, José E. Martinez⁵, José R. Provenza⁶, Aline Ranzolin⁷, Marcos Renato Assis⁸, Vivian D. Pasqualin⁹ and Robert M. Bennett¹⁰, ¹Rheumatology, Universidade Federal do Paraná, Curitiba, Brazil, ²Rheumatology, Universidade Federal de São Paulo, São Paulo, Brazil, ³Rheumatology, Santa Casa de Campo Grande, Campo Grande, Brazil, ⁴Rheumatology, Universidade Federal de de São Paulo, São Paulo, Brazil, ⁵Rheumatology, Pontifícia Universidade Católica de São Paulo, Sorocaba, Brazil, ⁶Rheumatology, Pontifícia Universidade Católica de Campinas, Campinas, Brazil, ⁷Universidade Federal de Pernambuco, Recife PE, Brazil, ⁸Faculdade de Medicina de Marilia, Marilia, Brazil, ⁹Pontifícia Universidade Católica do Paraná, Curitiba, Brazil, ¹⁰Medicine & Nursing, Oregon Health & Science Univ, Portland, OR
Background/Purpose: General health evaluation questionnaires are important instruments in assessing the impact of disorders that affect multiple domains of a patient´s life. The Fibromyalgia Impact Questionnaire…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].